Royal Philips NV's healthcare technology group saw a decline in nominal sales for the first quarter, despite strong growth in Western European markets.

The Dutch company posted first-quarter revenue of €3.91 billion (equivalent to $4.57 billion), compared with €4.1 billion in the same period last year. According to consensus analyst estimates, market expectations had been for first-quarter sales of €3.88 billion.

On a comparable basis, however, sales increased by 4% year-on-year. The company attributed the growth in comparable sales to improved performance in North America, across European markets, and in the personal health business segment. Sales in Europe rose under both nominal and comparable measures.

Net profit for the first quarter of 2026 was €151 million, up from €76 million in the prior-year period. Analysts had expected net profit of €66 million.

Royal Philips maintained its full-year outlook, projecting an adjusted EBITA margin between 12.5% and 13.0%. The company also expects full-year comparable sales growth in the range of 3% to 4.5%.